ArticleEuropean journal of public health2026
Overcoming barriers to the prescription/dispensation of take-home naloxone among French primary care professionals: a regional training initiative.
Article in European journal of public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Opioid-related mortality is a global issue, and France shows high opioid use disorder indicators. Despite recommendations for wider take-home-naloxone distribution, access remains limited in France, and many primary care professionals lack training. The SINFONI project aims to enhance naloxone education for these providers. A motion-design training program was created and sent to general practitioners (GPs) and pharmacists. A total of 138 GPs and 207 pharmacists participated in the knowledge assessment before and after training. Post-training, significant improvements were observed, and the greatest knowledge gains were in understanding naloxone's safety (P < .001). Our findings primarily identified critical "red flags" that may hinder prescription and dispensing practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.